Newleos Therapeutics is dedicated to providing a new dawn or 'eos' for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. The company's clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/03/25 | $93,500,000 | Series A |
Arkin Bio Ventures DCVC Bio Goldman Sachs  Longwood Fund Novo Holdings | undisclosed |
